Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
View Patent ↗The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.
1. A method of treating Crohn's disease or ulcerative rectocolitis, comprising administering to a mammal in need thereof a compound that activates a PPARγ receptor, and represented by the general formula (I)
in which
R 1 and R 2 , which may be identical or different, are selected from the group consisting of —H or a linear or branched alkyl group having from 1 to 6 carbon atoms;
Y is selected from the group consisting of —H, —OH, —OR 3 , or —COOH wherein R 3 is selected from the group consisting of phenyl, benzyl, —CF 3 , —CF 2 CF 3 , vinyl, allyl, and a linear or branched alkyl group having from 1 to 6 carbon atoms;
Z is —CH(OR 3 )COOH, in which R 3 is selected from the group consisting of H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms; or salts thereof.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein Y is H.
4. The method of claim 1 , wherein Z is —CH(OR 3 )COOH, wherein R 3 is selected from the group consisting of —CH 3 or —CH 2 CH 3 .
5. A method of treating Crohn's disease in a patient in need thereof, comprising administering an effective amount of a compound having PPARγ receptor activity, wherein the compound is selected from the group consisting of:
6. The method of claim 1 , wherein the compound is selected from the group consisting of: ±−2-methoxy-3-(3′-aminophenyl)propionic acid and ±−2-methoxy-3-(4′-aminophenyl)propionic acid.
7. The method of claim 1 , wherein the chronic inflammatory disease is Crohn's disease.
8. The method of claim 1 , wherein the chronic inflammatory disease is ulcerative rectocolitis.
9. A method of treating Crohn's disease in a mammal in need thereof, comprising administering to said mammal a compound having PPARγ receptor activity, wherein the compound is represented by:
or salts thereof.
10. The method of claim 9 , wherein the compound is in an enantiomerically pure R or S form.